Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch of its patent-pending ...
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, and Family Medicine Specialists (FMS), a ...
Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, is making progress in gaining broad access to Medicare reimbursement for its Epi+Gen CHD™ and ...
Cardio Diagnostics CDIO, a leader in artificial intelligence-driven precision cardiovascular medicine, has published a potentially revolutionary study in the Journal of the American Heart Association ...
February 4, 2009 (Bloomington, Indiana) - A new personal health assessment could prove to be the difference between good health and heart disease for many people. TheViveda Cardio Assessment, recently ...
The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for ...
Deepak L. Bhatt, MD, MPH: Let me turn now to Dr Navar to discuss what I think is an important part of the discussion. She’s done a lot of work on this. How do we actually estimate patients’ risk for ...
NEW YORK, Aug. 31 (UPI) --A single blood test that measures inflammation and fat can predict women's risk for cardiovascular disease 30 years later, a new Harvard study suggests. The findings, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results